Get the Stockscreener App
0.8503
5.52%
-0.0497
Lexaria Bioscience Corp stock is traded at $0.8503, with a volume of 221.54K.
It is down -5.52% in the last 24 hours and up +0.04% over the past month.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
See More
Previous Close:
$0.90
Open:
$0.87
24h Volume:
221.54K
Relative Volume:
1.68
Market Cap:
$16.63M
Revenue:
$411.00K
Net Income/Loss:
$-4.85M
P/E Ratio:
-1.9325
EPS:
-0.44
Net Cash Flow:
$-4.88M
1W Performance:
-13.06%
1M Performance:
+0.04%
6M Performance:
-51.96%
1Y Performance:
-78.64%
1-Day Range:
$0.835
$0.8999
1-Week Range:
$0.8267
$1.02
52-Week Range:
$0.7941
$4.38
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Name
Lexaria Bioscience Corp
Sector
Industry
Phone
250-765-6424
Address
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
0.8503 | 17.60M | 411.00K | -4.85M | -4.88M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexaria Bioscience Corp Stock (LEXX) Latest News
How does Lexaria Bioscience Corp. Equity Warrant generate profit in a changing economyWealth Building Target Finder For Every Investor - jammulinksnews.com
When is Lexaria Bioscience Corp. Equity Warrant stock expected to show significant growthValue Investing Recommendation For Every Investor - jammulinksnews.com
Using fundamentals and technicals on Lexaria Bioscience Corp. Equity WarrantChart Scanner for Swing Trade Timing - Newser
Why Lexaria Bioscience Corp. Equity Warrant stock attracts strong analyst attentionShort Window Trade Insight Plan - beatles.ru
How strong is Lexaria Bioscience Corp. Equity Warrant company’s balance sheetSmart Portfolio Planner With Proven Results - jammulinksnews.com
What MACD and RSI say about Lexaria Bioscience Corp.Free Value Investing Picks With Stability - Newser
Why Lexaria Bioscience Corp. stock attracts strong analyst attentionFree Community Entry Consensus Trade Ideas - Newser
Published on: 2025-08-01 03:28:42 - Newser
What makes Lexaria Bioscience Corp. stock price move sharplyAI Risk Optimized Trade Forecast Planner - Newser
Heatmap analysis for Lexaria Bioscience Corp. and competitorsFree Alpha Focused Technical Trade Signals - Newser
Predicting Lexaria Bioscience Corp. Equity Warrant trend using moving averagesVolatility Analysis and Entry Risk Mapping - Newser
Can Lexaria Bioscience Corp. Equity Warrant recover in the next quarterBuy Point Strategy with Profit Protection - Newser
Order flow analysis tools used on Lexaria Bioscience Corp. Equity WarrantMonthly Trade Result and Signal Summary - Newser
What’s the recovery path for long term holders of Lexaria Bioscience Corp. Equity WarrantSafe Entry Strategy with High Win Rate - Newser
Forecasting Lexaria Bioscience Corp. price range with options dataReal-Time Signal Tracking with Entry Level - Newser
What catalysts could drive Lexaria Bioscience Corp. Equity Warrant stock higher in 2025AI Powered Forecasts With Proven Results - jammulinksnews.com
Will Lexaria Bioscience Corp. continue its uptrendGrowth Focused Entry Plan Suggestions Issued - metal.it
What are the latest earnings results for Lexaria Bioscience Corp.Wealth Building Target Finder To Watch Now - jammulinksnews.com
Published on: 2025-07-31 00:52:26 - Newser
How Lexaria Bioscience Corp. stock performs during market volatilityAI Screener for Daily Stock Forecast - Newser
Lexaria Bioscience Corp. stock outlook for YEARSecure Entry Point Finder with Analysis - Newser
Lexaria Bioscience director McKechnie buys $4.5k in shares By Investing.com - Investing.com India
Lexaria Bioscience director Docherty buys $4,988 in shares By Investing.com - Investing.com Canada
Lexaria Bioscience director Docherty buys $4,988 in shares - Investing.com Australia
Lexaria Bioscience CEO Christopher Richard buys $13,641 in shares By Investing.com - Investing.com South Africa
Lexaria Bioscience secretary Carle buys $682 in shares By Investing.com - Investing.com Canada
Lexaria Bioscience CEO Christopher Richard buys $13,641 in shares - Investing.com Australia
Lexaria Bioscience secretary Carle buys $682 in shares - Investing.com
Lexaria Bioscience Corp. Equity Warrant stock volume spike explainedStrategy Playbook for Risk Controlled Trades - Newser
Has Lexaria Bioscience Corp. formed a bullish divergenceSafe Entry Strategy with High Win Rate - Newser
Market reaction to Lexaria Bioscience Corp.’s recent newsBuy Alert Based on RSI and Volume - Newser
Is Lexaria Bioscience Corp. Equity Warrant trending in predictive chart modelsLow Drawdown Picks with Weekly Updates - Newser
Using data models to predict Lexaria Bioscience Corp. stock movementFree Daily Top Performing Stock Insights - Newser
Is Lexaria Bioscience Corp. Equity Warrant Stock a Smart Buy in 2025 Investment Analysis InsideProven Entry Plan With Low Risk Shared - metal.it
How to recover losses in Lexaria Bioscience Corp. stockFree Daily Chart Pattern Stock Forecast - Newser
Lexaria Bioscience Corp. Pullback Analyzed — Is It Time to ExitQuick Gain Stock Watch With Indicators Reviewed - metal.it
Trapped Investors in Lexaria Bioscience Corp. Await Breakout SignalCommunity Entry Consensus Trade Ideas Shared - metal.it
Chart Analysts Warn of Resistance Near Lexaria Bioscience Corp. Equity Warrant PriceRisk Controlled Picks With Real Returns Outlined - metal.it
H.C. Wainwright lowers Lexaria Bioscience stock price target on share dilution - Investing.com Nigeria
H.C. Wainwright lowers Lexaria Bioscience stock price target on share dilution By Investing.com - Investing.com South Africa
Lexaria Bioscience Corp Stock (LEXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):